Tay-Sachs Disease Clinical Trials and Treatments

Tay-Sachs disease is an autosomal recessive lysosomal storage disorder caused by mutations in the HEXA gene, resulting in complete or near-complete deficiency of hexosaminidase A enzyme. Without adequate enzyme activity, GM2 gangliosides accumulate progressively within neurons and other cells, particularly affecting the central nervous system. The classical infantile form presents around 3-6 months of age with developmental regression, loss of previously acquired skills, hypotonia, and developmental delay.

The most common symptoms of Tay-Sachs Disease include Progressive developmental regression, Loss of purposeful movements and muscle tone, Cherry-red spot on the macula of the eye, Seizures, often by age 6 months, Blindness and deafness, among others. Tay-Sachs Disease affects approximately 1 in 30,000 births; 1 in 3,500 in Ashkenazi Jewish population. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Tay-Sachs Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Gene therapy for Tay-Sachs disease represents a major advancement, with intracerebral and intrathecal gene therapy approaches undergoing clinical testing. The National Tay-Sachs and Allied Diseases Association maintains current trial information and provides essential support for families.

As of October 21, 2026, no current FDA drug label names Tay-Sachs Disease as a condition the drug treats.

Tay-Sachs Disease is caused by variants in the HEXA gene. Variants that leave residual hexosaminidase A activity cause the juvenile and late-onset forms.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child. The condition affects approximately 1 in 30,000 births; 1 in 3,500 in Ashkenazi Jewish population. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Tay-Sachs Disease looks at the HEXA gene. Variants that leave residual hexosaminidase A activity cause the juvenile and late-onset forms.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Tay-Sachs Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Tay-Sachs Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.